Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
91
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Thrombocytopenia
Interventions
BIOLOGICAL:
PF-06835375
Sponsor
Pfizer